TY - JOUR
T1 - Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors
AU - Ando, Koji
AU - Ozonoff, Al
AU - Lee, Shin Yin
AU - Voisine, Michael
AU - Parker, Julian Taylor
AU - Nakanishi, Ryota
AU - Nishimura, Sho
AU - Yang, Jing
AU - Grace, Zhao
AU - Tran, Ben
AU - Diefenbach, Thomas J.
AU - Maehara, Yoshihiko
AU - Yasui, Hiroshi
AU - Irino, Tomoyuki
AU - Salgia, Ravi
AU - Terashima, Masanori
AU - Gibbs, Peter
AU - Ramanathan, Ramesh K.
AU - Oki, Eiji
AU - Mori, Masaki
AU - Kulke, Matthew
AU - Hartshorn, Kevan
AU - Bharti, Ajit
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2021/6
Y1 - 2021/6
N2 - Purpose: The camptothecin (CPT) analogs topotecan and irinotecan specifically target topoisomerase I (topoI) and are used to treat colorectal, gastric, and pancreatic cancer. Response rate for this class of drug varies from 10% to 30%, and there is no predictive biomarker for patient stratification by response. On the basis of our understanding of CPT drug resistance mechanisms, we developed an immunohistochemistry-based predictive test, P-topoI-Dx, to stratify the patient population into those who did and did not experience a response. Patients and Methods: The retrospective validation studies included a training set (n = 79) and a validation cohort (n = 27) of gastric cancer (GC) patients, and 8 cohorts of colorectal cancer (CRC) patient tissue (n = 176). Progression-free survival for 6 months was considered a positive response to CPT-based therapy. Formalin-fixed, paraffin-embedded slides were immunohistochemically stained with anti–phospho-specific topoI-Serine10 (topoI-pS10), quantitated, and analyzed statistically. Results: We determined a threshold of 35% positive staining to offer optimal test characteristics in GC. The GC (n = 79) training set demonstrated 76.6% (95% confidence interval, 64-86) sensitivity; 68.8% (41-88) specificity; positive predictive value (PPV) 92.5% (81-98); and negative predictive value (NPV) 42.3% (24-62). The GC validation set (n = 27) demonstrated 82.4% (56-95) sensitivity and 70.0% (35-92) specificity. Estimated PPV and NPV were 82.4% (56-95) and 70.0% (35-92) respectively. In the CRC validation set (n = 176), the 40% threshold demonstrated 87.5% (78-94) sensitivity; 70.0% (59-79) specificity; PPV 70.7% (61-79); and NPV 87.0 % (77-93). Conclusion: The analysis of retrospective data from patients (n = 282) provides clinical validity to our P-topoI-Dx immunohistochemical test to identify patients with disease that is most likely to respond to topoI inhibitors.
AB - Purpose: The camptothecin (CPT) analogs topotecan and irinotecan specifically target topoisomerase I (topoI) and are used to treat colorectal, gastric, and pancreatic cancer. Response rate for this class of drug varies from 10% to 30%, and there is no predictive biomarker for patient stratification by response. On the basis of our understanding of CPT drug resistance mechanisms, we developed an immunohistochemistry-based predictive test, P-topoI-Dx, to stratify the patient population into those who did and did not experience a response. Patients and Methods: The retrospective validation studies included a training set (n = 79) and a validation cohort (n = 27) of gastric cancer (GC) patients, and 8 cohorts of colorectal cancer (CRC) patient tissue (n = 176). Progression-free survival for 6 months was considered a positive response to CPT-based therapy. Formalin-fixed, paraffin-embedded slides were immunohistochemically stained with anti–phospho-specific topoI-Serine10 (topoI-pS10), quantitated, and analyzed statistically. Results: We determined a threshold of 35% positive staining to offer optimal test characteristics in GC. The GC (n = 79) training set demonstrated 76.6% (95% confidence interval, 64-86) sensitivity; 68.8% (41-88) specificity; positive predictive value (PPV) 92.5% (81-98); and negative predictive value (NPV) 42.3% (24-62). The GC validation set (n = 27) demonstrated 82.4% (56-95) sensitivity and 70.0% (35-92) specificity. Estimated PPV and NPV were 82.4% (56-95) and 70.0% (35-92) respectively. In the CRC validation set (n = 176), the 40% threshold demonstrated 87.5% (78-94) sensitivity; 70.0% (59-79) specificity; PPV 70.7% (61-79); and NPV 87.0 % (77-93). Conclusion: The analysis of retrospective data from patients (n = 282) provides clinical validity to our P-topoI-Dx immunohistochemical test to identify patients with disease that is most likely to respond to topoI inhibitors.
KW - Colorectal cancer
KW - Gastric cancer
KW - IHC assay
KW - P-topoI-Dx
UR - http://www.scopus.com/inward/record.url?scp=85102579648&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102579648&partnerID=8YFLogxK
U2 - 10.1016/j.clcc.2020.11.005
DO - 10.1016/j.clcc.2020.11.005
M3 - Article
C2 - 33731288
AN - SCOPUS:85102579648
SN - 1533-0028
VL - 20
SP - e129-e138
JO - Clinical colorectal cancer
JF - Clinical colorectal cancer
IS - 2
ER -